1. Scrip
  2. >>Therapy Areas

Pfizer To Take Zinplava Rival Into Phase III For C Diff

 
• By Alexandra Shimmings

Pfizer will start a Phase III trial for its Clostridium difficile vaccine by the middle of the year, taking aim at the chinks in the armour of Merck & Co’s recently approved Zinplava, but it still trails its rival from Sanofi.

Clostridium
Clostridium

Top-line data for Pfizer Inc.’s investigational vaccine PF-06425090 for the prevention of Clostridium difficile infection from a pre-planned interim analysis are strong enough to warrant taking the product into a Phase III trial due to start in the first half, the company says.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.